ArticleOral diseases2025
Serum Biomarkers and Their Clinical Correlates in Traumatic Trigeminal Neuropathy: A Pilot Study.
Article in Oral diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
objectivesThis study aims to investigate the serum biomarker levels in patients with painful post-traumatic trigeminal neuropathy (PPTTN) and explore the associations between these biomarkers and the clinical and psychological characteristics of the patients. MATERIALS AND
methodsA total of 32 patients with PPTTN were included. Serum levels of various cytokines and neurotrophic factors were measured. Patients were assessed for clinical and psychological characteristics, including pain severity, pain interference, numbness severity, and symptom duration as well as psychological factors using validated questionnaires.
resultsNo significant differences in serum biomarker levels were found based on age, sex, pain severity, pain interference, or type of injured nerve after adjusting multiple comparisons. Significant differences were observed in interleukin-8 (IL-8) and brain-derived neurotrophic factor (BDNF) levels based on symptom duration, with higher levels in patients whose symptoms lasted for more than 6 months. Spearman correlation analysis revealed strong relationships between clinical and psychological variables. Pain outcomes were more strongly associated with psychological factors than with serum biomarkers.
conclusionIL-8 and BDNF may be biomarkers for disease progression in PPTTN based on symptom duration, with pain outcomes more related to psychological factors rather than serum biomarker levels, highlighting the need for psychological support in management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.